AUPH analyst estimates
Aurinia Pharmaceuticals (AUPH) analyst ratings, the average price target and its range, and every firm's latest call.
AUPH analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Aurinia Pharmaceuticals price target raised to $16 from $15 at RBC Capital | $16.00 |
| Dec 3, 2025 | Leerink Partners | Aurinia Pharmaceuticals downgraded to Market Perform from Outperform at Leerink | $16.00 |
| Nov 4, 2025 | RBC Capital | Aurinia downgraded to Sector Perform from Outperform at RBC Capital | $15.00 |
| Sep 6, 2024 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Aurinia Pharmaceuticals (AUPH) | $13.00 |
| May 2, 2024 | Jefferies | Aurinia Pharmaceuticals (AUPH) PT Lowered to $6 at Jefferies | $6.00 |
| Jan 4, 2023 | RBC Capital | RBC Capital Maintains Outperform on Aurinia Pharmaceuticals, Raises Price Target to $11 | $11.00 |
| Aug 9, 2022 | H.C. Wainwright | HC Wainwright & Co. Maintains Buy on Aurinia Pharmaceuticals, Lowers Price Target to $26 | $26.00 |
| Aug 8, 2022 | Oppenheimer | Oppenheimer Maintains Outperform on Aurinia Pharmaceuticals, Lowers Price Target to $13 | $13.00 |
| May 5, 2022 | H.C. Wainwright | HC Wainwright & Co. Maintains Buy on Aurinia Pharmaceuticals, Lowers Price Target to $30 | $30.00 |
| Apr 28, 2022 | RBC Capital | RBC Capital Maintains Outperform on Aurinia Pharmaceuticals, Lowers Price Target to $22 | $22.00 |
- 4 firms rate AUPH: 2 buy, 2 hold, 0 sell.
- The average price target is $16.00 from 1 analysts, from $16.00 to $16.00.
Updated 2026-11-02 23:12 UTC